Next Article in Journal
Time Trends in the Incidence of Long-Term Mortality in T2DM Patients Who Have Undergone a Lower Extremity Amputation. Results of a Descriptive and Retrospective Cohort Study
Next Article in Special Issue
Heterogeneity of Vascular Endothelial Cells, De Novo Arteriogenesis and Therapeutic Implications in Pancreatic Neuroendocrine Tumors
Previous Article in Journal
3D Bioprinted Human Cortical Neural Constructs Derived from Induced Pluripotent Stem Cells
Previous Article in Special Issue
Role of MYC-miR-29-B7-H3 in Medulloblastoma Growth and Angiogenesis
Open AccessReview

Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition

1
Department of Research and Advanced Tumour Diagnostics, Immunopathology and Tumour Biomarkers Unit/Bio-proteomics Facility, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, 33081 Aviano, Italy
2
Department of Women’s and Children’s Health, Clinic of Paediatric Haemato-Oncology, University of Padua, 35127 Padua, Italy
3
Institute of Paediatric Research—Fondazione Città della Speranza, 35127 Padua, Italy
4
Pediatric Radiotherapy and AYA Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(10), 1596; https://doi.org/10.3390/jcm8101596
Received: 27 July 2019 / Revised: 12 September 2019 / Accepted: 23 September 2019 / Published: 2 October 2019
The ligation of programmed cell death 1 (PD-1) with programmed cell death ligand PD-L activates the immune checkpoint leading to T-cell dysfunction, exhaustion, and tolerance, especially in Hodgkin lymphoma (HL) where the PD-L/ Janus kinase (Jak) signaling was frequently found altered. Anti-PD-1 or anti-PD-L1 monoclonal antibodies can reverse this immune checkpoint, releasing the brake on T-cell responses. The characterization of the mechanisms regulating both the expression of PD-1 and PD-L and their function(s) in HL is ongoing. We provide in this review the recent findings focused on this aim with special attention on the major research topics, such as adverse events and resistance to PD-1–PD-L1 inhibitor treatment, together with a part about angiogenesis, extracellular vesicles, and microbiome in HL pathogenesis. View Full-Text
Keywords: Hodgkin lymphoma; PD-1; PD-L1; EBV; cytokines; extracellular vesicles; adverse events; angiogenesis; immune checkpoint inhibitors Hodgkin lymphoma; PD-1; PD-L1; EBV; cytokines; extracellular vesicles; adverse events; angiogenesis; immune checkpoint inhibitors
Show Figures

Figure 1

MDPI and ACS Style

De Re, V.; Caggiari, L.; Repetto, O.; Mussolin, L.; Mascarin, M. Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition. J. Clin. Med. 2019, 8, 1596.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop